Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu vaccine may tame heart inflammation, small study hints

NCT ID NCT06508437

Disease control Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the flu vaccine can reduce inflammation in people with stable coronary artery disease. Inflammation plays a key role in heart disease progression. The trial involved 47 adults aged 60 and older with stable heart disease, who received the flu vaccine either right away or after a delay. Researchers measured changes in blood markers of inflammation, like C-reactive protein, to see if the vaccine had a direct calming effect on the immune system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

47 people

The number who actually took part.

Started

Oct 2024

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged ≥ 60 years. * With documented stable coronary artery disease. * Subjects who, in the opinion of the investigator, can comply with the protocol requirements (i.e., show up for the follow-up visit and be able to converse with study staff). * Signature of free, written and informed consent by the patient. * Affiliation to a French social security system. Exclusion Criteria: * History of serious reaction to influenza vaccine or refusal of vaccination or contraindication to vaccination. * Participant has received the influenza vaccine within \<6 months or another vaccine. * Acute infection within \<3 months or acute worsening of chronic diseases. * Severe neurocognitive disorders (inability to give informed consent). * Pre-existing medical conditions or medications involving the immune system (rheumatoid arthritis or other inflammatory conditions or active cancer, recent use (within the past year) of immunosuppressive or modulating agents, including oral steroids, chemotherapy, or radiation therapy) . * Cardiovascular surgery or other interventions within 6 months preceding the study or planned during the follow-up period. * Patient's wish or clinical situation requiring co-administration with other vaccines or any factor hindering monitoring. * Patient under guardianship, curatorship or safeguard of justice.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder Coronary Disease Inflammation inflammatory disease influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Coronary artery disease Inflammatory response

Contacts and locations

Locations

  • Chru de Trousseau

    Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.